Lipitor in perspective: With $6.45 bil. in annual sales in 2001, Pfizer's Lipitor generates more revenues than the annual Gross Domestic Product of 78 countries, based on calculations of purchasing power parity by the Central Intelligence Agency. If Lipitor meets growth expectations in 2002, it should surpass the GDP of Tajikistan ($7.3 bil.)....Zocor heart protection study: Merck will present data on the effect of Zocor (simvastatin) in the 20,000-patient Heart Protection Study at the American College of Cardiology meeting in March. Preliminary results show that Zocor "reduced the risk of heart attacks and stroke by at least one-third," company says. A filing based on the data is planned for this year...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
